Partnership
Partner with Scope Biosciences on CRISPR-based Diagnostic Co-Development
We’re looking for partners to co-develop rapid, accurate molecular diagnostics using our plug-and-play CRISPR platform.
- Development
Start-ups and SMEs
www.scopebio.comWageningen, NetherlandsScope Biosciences B.V. is a Dutch biotech company pioneering next-generation molecular diagnostics through its patented scopeDx® platform, based on a unique type III CRISPR-Cas system. A spin-off from Wageningen University, Scope Biosciences aims to democratize diagnostics by combining the speed and ease-of-use of immunoassays with the accuracy of PCR, delivering results within 30 minutes at the point-of-care. Under the EU-funded EIC Transition project (2024–2026), the company is advancing scopeDx® from proof-of-concept to a complete sample-to-answer solution for clinical applications, emphasizing modularity, specificity (SNP-level), and on-site usability
Objectives
Topics
Partnership
Partner with Scope Biosciences on CRISPR-based Diagnostic Co-Development
We’re looking for partners to co-develop rapid, accurate molecular diagnostics using our plug-and-play CRISPR platform.
Investment
Invest in the Future of CRISPR Diagnostics
Join us in shaping decentralized diagnostics with our proven CRISPR platform—now advancing toward clinical validation and scale-up.